Broadcom
AVGO
Alibaba
BABA
NVIDIA
NVDA
Tesla
TSLA
Advanced Micro Devices
AMD
US Stock MarketDetailed Quotes
ACHV Achieve Life
- 3.090
- +0.020+0.65%
Close Jan 17 16:00 ET
106.26MMarket Cap-2.76P/E (TTM)
3.140High3.020Low379.92KVolume3.090Open3.070Pre Close1.17MTurnover1.30%Turnover RatioLossP/E (Static)34.39MShares5.59052wk High3.39P/B90.05MFloat Cap3.02052wk Low--Dividend TTM29.14MShs Float1856247.281Historical High--Div YieldTTM3.91%Amplitude2.000Historical Low3.077Avg Price1Lot Size
Trending US Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Achieve Life Stock Forum
Achieve Life Sciences Announces Critical Milestone Successfully Reached in ORCA-OL Cytisinicline Clinical Trial Required for NDA Submission
Tuesday, 7th January at 8:30 am
Over 300 Participants Have Completed Cumulative Six Months of Cytisinicline Treatment in the ORCA-OL Trial, Completing the Long-Term Exposure Requirement for NDA Submission
ORCA-OL Long-Term Exposure Timelines Remain on Track with No Safety Concerns Identified
Planned Cytisinicline NDA Submission on...
Achieve Life Sciences Announces Initiation of ORCA-OL Clinical Trial Evaluating Long-Term Exposure of Cytisinicline in People who Smoke or Use Nicotine E-Cigarettes
Achieve Life Sciences has initiated the ORCA-OL clinical trial to evaluate the long-term safety of cytisinicline, a treatment for smoking and nicotine dependence. The open-label trial involves 29 U.S. sites and aims to collect data required for a New Drug Application (NDA) submission expected in the first ...
NEWS
Achieve Life Sciences Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine
$Taysha Gene Therapies (TSHA.US)$ 21% FY 2023 results
$TFF Pharmaceuticals (TFFP.US)$ 14% Clinical programs update
$Jaguar Health (JAGX.US)$ 14% Crofelemer commercialization
$Acelyrin (SLRN.US)$ 4% Ph1/2 positive data
$Delcath Systems (DCTH.US)$ 3% Closes $7M private placement
$Sellas Life Sciences (SLS.US)$ 0% Closes $20M offering & private placement
$Immunic (IMUX.US)$ 1% Patent notice of allowance
$Nurix Therapeutics (NRIX.US)$ 0...
No comment yet